Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group

scientific article published on 01 February 1994

Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/0090-4295(94)90221-6
P698PubMed publication ID8116135

P2093author name stringL Weissbach
A Hinke
M W Kühn
P433issue2 Suppl
P407language of work or nameEnglishQ1860
P921main subjectmetastatic prostate carcinomaQ55779807
prostate cancerQ181257
P304page(s)61-67
P577publication date1994-02-01
P1433published inUrologyQ7900884
P1476titlePrimary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group
P478volume43

Reverse relations

cites work (P2860)
Q56519091Estramustine Phosphate Sodium
Q28290608Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer
Q38574476Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer
Q34393961How is androgen-dependent metastatic prostate cancer best treated?
Q77522861Systemic treatment for prostate cancer

Search more.